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Abstract
Background: Cycloset™ is a quick-release formulation of bromocriptine mesylate, a dopamine agonist, which in animal
models of insulin resistance and type 2 diabetes acts centrally to reduce resistance to insulin- mediated suppression of
hepatic glucose output and tissue glucose disposal. In such animals, bromocriptine also reduces hepatic triglyceride
synthesis and free fatty acid mobilization, manifesting decreases in both plasma triglycerides and free fatty acids. In clinical
trials, morning administration of Cycloset™ either as monotherapy or adjunctive therapy to sulfonylurea or insulin
reduces HbA1c levels relative to placebo by 0.55–1.2. Cycloset™ therapy also reduces plasma triglycerides and free fatty
acid by approximately 25% and 20%, respectively, among those also receiving sulfonylurea therapies. The effects of once-
daily morning Cycloset™ therapy on glycemic control and plasma lipids are demonstrable throughout the diurnal portion
of the day (7 a.m. to 7 p.m.) across postprandial time points.
Methods/Design: 3,095 individuals were randomized in a 2:1 ratio into a one year trial aimed to assess the safety and
efficacy of Cycloset™ compared to placebo among individuals receiving a variety of treatments for type 2 diabetes.
Eligibility criteria for this randomized placebo controlled trial included: age 30–80, HbA1c ≤ 10%, diabetes therapeutic
regimen consisting of diet or no more than two hypoglycemic agents or insulin with or without one additional oral agent
(usual diabetes therapy; UDT). The primary safety endpoint will test the hypothesis that the rate of all-cause serious
adverse events after one year of usual diabetes therapy (UDT) plus Cycloset™ is not greater than that for UDT plus
placebo by more than an acceptable margin defined as a hazard ratio of 1.5 with a secondary endpoint analysis of the
difference in the rate of serious cardiovascular events, (myocardial infarction, stroke, coronary revascularization or
hospitalization for or angina or congestive heart failure). Efficacy analyses will evaluate effects of Cycloset™ versus
placebo on change from baseline in HbA1c, fasting glucose, body weight, waist circumference, blood pressure and plasma
lipids.
Discussion: This study will extend the current data on Cycloset™ safety, tolerability and efficacy in individuals with type
2 diabetes to include its effects in combination with thiazolodinediones, insulin secretagogues, metformin, alpha-
glucosidase inhibitors and exogenous insulin regimens.
Trial registration: clinical trials.gov NCT00377676
Published: 25 June 2007
BMC Endocrine Disorders 2007, 7:3 doi:10.1186/1472-6823-7-3
Received: 12 April 2007
Accepted: 25 June 2007
This article is available from: http://www.biomedcentral.com/1472-6823/7/3
© 2007 Scranton et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Endocrine Disorders 2007, 7:3 http://www.biomedcentral.com/1472-6823/7/3
Page 2 of 7
(page number not for citation purposes)
Background
Reduced insulin-mediated glucose disposal and impaired
suppression of endogenous (hepatic) glucose production
are dominant metabolic features of the obese state. [1] It
has been estimated that 60–80 percent of type 2 diabetic
patients are obese. [2] Among representative species of all
the major vertebrate classes of animals, the development
of obesity and its accompanying insulin resistance has cer-
tain adaptive advantages. This adaptation improves sur-
vival in times of seasonal famine.[3] Many vertebrate
species develop obesity and insulin resistance in prepara-
tion for hibernation, migration or during over-wintering
periods when food availability is extremely low.[4] Exten-
sive experimental evidence indicates that circadian neu-
roendocrine rhythms play a pivotal role in the
development of seasonal changes in body fat stores and
insulin sensitivity. Specifically, temporal changes in the
interaction of two distinct circadian neural circadian oscil-
lations, mediated in part by dopaminergic and serotoner-
gic neurotransmitter activity, have been shown to regulate
the dramatic seasonal alterations in body weight and
body composition that are characteristic of all vertebrate
classes from teleosts to mammals.[3] Additional data
obtained in pigs and rats suggest that similar mechanisms
may play a role in the development of nonseasonal (e.g.,
aging-related) obesity and insulin resistance.[5,6]
Bromocriptine mesylate, an ergot derivative, is a sym-
patholytic dopamine D2 receptor agonist that can exert
inhibitory effects on serotonin turnover in the central
nervous system.[7] Available evidence suggests that bro-
mocriptine can reverse many of the metabolic alterations
associated with insulin resistance and obesity by resetting
central (hypothalamic) circadian organization of
monoamine neuronal activities.[8] Additionally,
dopamine agonist treatment reduces ventromedial, arcu-
ate and paraventricular hypothalamic drive for increased
hepatic glucose production, lipid synthesis and mobiliza-
tion, and insulin resistance. [9,10] When administered
systemically [11-13] or into the cerebral ventricle [14]
during the early hours of the light cycle, bromocriptine
prevents or reverses seasonal fattening, insulin resistance
and hyperinsulinemia, as well as decreases endogenous
(hepatic) glucose production in mammals.
Cycloset™ is a new quick-release oral formulation of bro-
mocriptine mesylate that has been employed in clinical
studies to examine the effectiveness of timed bromocrip-
tine administration to humans with metabolic disease
including type 2 diabetes. Cycloset™ has been shown to
reduce insulin resistance, glucose intolerance and hyperl-
ipidemia during Phase II clinical trials. In three Phase III
clinical trials, Cycloset™ significantly improved hyperglyc-
emia among obese individuals with type 2 diabetes [15]
Based on these study results, the FDA issued an approva-
ble letter for Cycloset™ for the treatment of type 2 diabe-
tes. Full approval is conditional, in part, on the
completion of a large, placebo-controlled, randomized
trial in persons with type 2 diabetes to evaluate fully drug-
related adverse events with a high degree of certainty. The
standard preparation of bromocriptine, Parlodel®, has
been used for over 25 years in persons with Parkinson's
disease, prolactinomas, acromegaly, infertility, and post-
partum lactation, many of whom also had diabetes. How-
ever, there have been no prospective, randomized, pla-
cebo-controlled trials conducted which permit the
estimation of incidence rate differences and ratios neces-
sary for ruling out a clinically meaningful increased risk
for adverse events in a population of persons with type 2
diabetes. This study will provide data that permits the esti-
mation of serious adverse event incidence rate differences
and ratios between Cycloset™ and placebo when these
agents are added to usual diabetes therapy. In addition to
the evaluation of safety parameters, we intend to evaluate
pre-specified efficacy parameters among patient sub-
groups. Specifically we intend to assess changes in Hba1c
among a subgroup of the study subjects that were not ade-
quately controlled on metformin and sulfonylurea ther-
apy. Clinical studies that combined Cycloset™ with
metformin were not part of the original Cycloset™ clinical
program because metformin was not commercially avail-




The primary objective of the study is to determine in sub-
jects with type 2 diabetes receiving Usual Diabetes Ther-
apy (UDT) and HbA1c ≤ 10%:
1. Whether add-on therapy with Cycloset™ results in all-
cause rates of serious adverse events that are not higher
than that of placebo by a pre-defined margin.
2. Whether add-on therapy with Cycloset™ results in dis-
ease-specific rates of serious cardiovascular adverse events
that are not higher than that of placebo by non-inferiority
margin of 1.5.
While the primary purpose of this study is to establish the safety
profile of Cycloset™ in type 2 diabetes, any potential positive
cardiovascular benefits will be evaluated as well.
Analysis of efficacy
Hba1c changes from baseline to 24 weeks between
Cycloset™ and Placebo among subjects with a baseline
Hba1c of ≥ 7.5% among the following subgroups:
1. Treated at baseline with any Oral hypoglycemic agent
(OHA) including injectable insulin secretagoguesBMC Endocrine Disorders 2007, 7:3 http://www.biomedcentral.com/1472-6823/7/3
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a. Metformin plus or minus one OHA or injectable insulin
secretagogue
b. Sulphonylurea plus or minus one OHA or injectable
insulin secretagogue
2. Treated at baseline with Metformin and one sulphony-
lurea
Study design and setting
This is a double blind, multi-center, placebo-controlled,
parallel group, non-inferiority study in subjects with type
2 diabetes, comparing usual diabetes therapy (UDT) plus
Cycloset™ to UDT plus placebo. Following a two-week
lead-in period, 3,095 subjects were randomized in a 2:1
ratio to UDT plus Cycloset™ or UDT plus placebo across
73 clinical centers in the United States and Puerto Rico.
Subjects were expected to remain on study treatment for
12 months, the first six weeks of which constitute a dose
titration period.
Ethical considerations
Full ethical approval for this study was obtained. An exter-
nal Data Monitoring and Safety Committee monitored
the study progress.
Study interventions
The experimental condition is Cycloset® in addition to the
subject's current diabetes therapeutic regimen and life-
style regimen. The control condition is placebo subject's
current diabetes therapeutic regimen and lifestyle regi-
men. The regimen must consist of either diet, oral
hypoglycemic agents (no more than 2), or insulin (alone
or with no more than 1 oral hypoglycemic agent). The
usual diabetes agents could not change during the first
three months of the study. However, the dosages of the
oral agents or insulin were modified as deemed appropri-
ate by the study site investigator to achieve target glycemic
goals recommended by the American Diabetes Associa-
tion [16] After three months, alterations in the diabetes
regimen were allowed if deemed necessary by the study
site investigator to adhere to the ADA guidelines for
achieving glycemic control. Prior to switching oral anti-
diabetic medication to an alternative anti-diabetic medi-
cation, titration of the current oral anti-diabetic medica-
tion up to maximum tolerated dose was preferred and
recommended to the study site investigators. However,
the change in the regimen could not include additions
that resulted in a final regimen that exceed two oral agents
(not including study medication), or insulin, plus one
oral agent (not including study medication).
Identification of eligible patients
Patients meeting the inclusion criteria were identified by
research centers across the United States which included
nineteen centers from the Veteran Affairs Healthcare Sys-
tem.
Confirmation of serious adverse events
Study site investigators elicited information regarding
serious adverse events. The study safety officer reviewed
all relevant safety data obtained from the study sites. Nar-
ratives were written from source documents. All serious
adverse events (SAE) were verified for accuracy of coding
for inclusion in the database. All SAEs were reviewed by
an external adjudication committee consisting of three
physicians (two cardiologists and one endocrinologist).
Whenever possible, the medical records corresponding
with the event were also reviewed.
Determining eligibility for the study
The principle investigator at each site reviewed the screen-
ing laboratories and medical history and assessed eligibil-
ity of screened study subjects (see table 1 inclusion and
exclusion criteria).
Patient follow-up procedures
After screening, patients were randomized and titrated to
the maximum tolerated dose of the study drug over a six
week period. After titration, subjects were seen every 3
months until study end (week 52) or early termination.
Subjects were contacted 30 days after completion of study
drug to record any adverse events occurring after treat-




Primary – all cause serious adverse events
Secondary – Composite of cardiovascular outcomes
(myocardial infarction, hospitalized angina or congestive
heart failure, stroke, or coronary revascularization)
Additional safety parameters
All adverse events, withdrawal due to an adverse event,
laboratory values, vital signs and ECG
Other clinical measures
• Fasting lipid profile (total, LDL, HDL cholesterol, trig-
lycerides) and
• HbA1c and
• Fasting plasma glucose level and
• Body weight, waist circumference, blood pressureBMC Endocrine Disorders 2007, 7:3 http://www.biomedcentral.com/1472-6823/7/3
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Sample size considerations
Sample size calculation for all-cause serious adverse events
In order to test the primary hypothesis at a one-sided
alpha = .05 and have a power of 1-β = 0.90 when the non-
inferiority margin is 1.5, the total number of subjects with
all-cause serious adverse events that must be observed
during the study is 235 with a sample size of 2,991
(assuming the placebo rate of 0.08).
Power calculation for serious cardiovascular adverse events
In order to test the hypothesis for serious cardiovascular
adverse events as for the primary endpoint at a one-sided
alpha = .05 when the non-inferiority margin is 1.5, the
final sample size of 3000 to 3300 subjects will provide at
least 62% power, assuming a hypothetical rate of events of
3.43%, or 103 to 113 cardiovascular serious adverse
events.
Power calculation for efficacy analysis
With an expected 0.5% difference in mean change in
HbA1c levels between the two treatment groups and a
standard deviation of HbA1c level of 1.0% and the base-
line and 24 week scores have a correlation of 0.50 then the
effect size is 0.5%/1.0% = 0.50. For the metformin/
sulphonylurea analysis, 160 subjects assuming a standard
deviation of 1.0% will provide a power of 90% power to
detect differences in mean changes of 0.5% or larger.
Endpoints
Safety
• The primary safety endpoint is the rate of time to first
treatment emergent all-cause serious adverse events.
• Secondary safety endpoints include disease-specific rate
of time to first treatment emergent serious cardiovascular
Table 1: Inclusion/Exclusion Criteria
Inclusion Criteria
Diagnosis Type 2 Diabetes ≥ 6 months prior to enrollment
Age 30–80 years
Hba1c at screening ≤ 10
Male or Female Female of child bearing age must use definitive contraceptive therapy
Exclusion
Taken Prescription sympathomimetic Taken seven days prior to screening
Drugs not permitted during study Ergot alkaloid derivatives, or anti-migrane medications
History of alcoholism or drug abuse Within 3 years of study entry
Donation of blood 30 days prior to study entry
Has received any experimental drug or used an experimental device Within 30 days of study entry
Pregnant or lactating women
Known hypersensitivity to any of the formulation components
Subjects with clinically significant major organ system disease:
• seizure disorder,
• significant gastroparesis or orthostatic hypotension (autonomic neuropathy),
• cerebrovascular accident in the previous 6 months,
• uncontrolled hypertension (systolic BP >160 or diastolic BP > 100 at screening)
• coronary artery bypass graft or coronary angioplasty in the previous 3 months, myocardial infarction in the previous 6 months, 
or unstable angina pectoris (chest pain at rest, worsening chest pain, or admission to the ER or hospital for chest pain) within the 
previous 3 months,
• congestive heart failure defined by NYHA as Class III or IV
• clinical nephrotic syndrome, or renal impairment with a serum creatinine > 1.4 mg/dl if female receiving treatment with 
metformin, > 1.5 mg/dl if male receiving treatment with metformin, and > 1.6 mg/dl in not on metformin,
• impaired liver function, including having AST or ALT greater than three times the upper limit of normal,
• active infection (e.g., HIV, hepatitis), or a history of severe infection during the 30 days prior to screening,
• major surgical operation during the 30 days prior to screening,
• cancer, other than non-melanoma skin or non metastatic prostate cancer within the past 5 years
• Any concurrent illness, other than diabetes mellitus, not controlled by a stable therapeutic regimen.
• Working rotating, varying or night shifts
• Patients taking unapproved herbal supplements that may be associated with a risk of cardiovascular events (such as ephedra, 
yohimbe etc)
• Patients who have started therapy with an erectile dysfunction drug within 2 weeks prior to screening; patients may not begin 
treatment with an erectile dysfunction drug during the study period; patients previously taking erectile dysfunction drugs should 
do so only under medical supervision.
• Subjects with circumstances or abnormalities (e.g., blindness or a history of non-compliance) that would interfere with the 
interpretation of safety or efficacy data or completion of the study.BMC Endocrine Disorders 2007, 7:3 http://www.biomedcentral.com/1472-6823/7/3
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Table 2: Study Flow Sheet
STUDY WEEK
- 2 - 101234561 22 43 65 2T e r m i n a t i o n 3
Assessment and Measurement Pre-Screen Screen ♠
HbA1c: Local lab < 10 ♣♣
Clinic Visit X X X X X X X X X
Medical History X
Concomitant Meds and Illnesses X X X X X X X X
Pregnancy test* X
Full Physical Exam, (Weight & Waist Circumference)1 XX X X
Blood pressure XX X X X X XX X X X
Record Adverse events (AE) X X X X X X X X
ECG X X X X
Telephone Call to Subject for AE's Reports X X X X
CBC & Plasma Sample X X X X
Chemistry, LAE♥ X⊕ XXXX
H b A 1 c X XXXX X
Fasting Plasma Glucose2 X X X X XXXX X
Fasting Lipid Profile♦2 XX X X
Notes on measures
♣ Local lab documentation of HbA1c ≤ 10 must be confirmed within 12 wks prior to conducting the Week-2 screening visit tests
♠ During Week-1 any labs or tests unable to be performed at screening should be completed
* To include pregnancy test (beta-HCG) in women of childbearing potential.
♥ CBC with differential and platelets, urinalysis, liver function (ALT, AST, alkaline phosphatase and total bilirubin), BUN, creatinine, Na, K, Cl, 
bicarbonate, calcium, phosphorus, and albumin.
♦ Total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol.
1. for body mass index and waist circumference to be measured on subject in the supine position at the level of the umbilicus
2. for BMI Obtained in the morning after a minimum 8 h overnight fast
3. A full 52-week assessment must be performed whenever a subject terminates the study early.
adverse events (myocardial infarction, stroke, inpatient
hospitalization for heart failure or angina, and revascular-
ization surgery) and the individual specific rates.
Efficacy
Other clinical measures include the impact (either posi-
tive or negative) of Cycloset™ on HbA1c, fasting plasma
glucose, weight, triglycerides lipids, blood pressure and
patient tolerability after six months of therapy. Inasmuch
as concurrent diabetes medications may change over the
52 week period with greater probability than at 24 weeks,
the primary efficacy analyses will be based on changes
from baseline to 24 weeks of treatment.
Statistical analysis – safety and other clinical measures
Safety
The Intention-To-Treat (ITT) analysis set will include all
subjects who were randomized to the study and received
at least one dose of study treatment (either Cycloset™ or
placebo) and will be used for evaluating all safety end-
points. The Evaluable Per-Protocol (EPP) analysis set will
consist of those ITT subjects with no major protocol vio-
lations and with at least one post-randomization meas-
urement of HbA1c, fasting plasma glucose, lipids, weight,
waist circumference or blood pressure. The primary anal-
ysis tested the hypothesis that the occurrence of all-cause
serious adverse events for Usual Diabetes Therapy (UDT)
plus Cycloset™ is not inferior to that for UDT plus placebo
by a predefined margin. For this study, the predefined
margin of non inferiority was defined as a hazard ratio
(UDT plus Cycloset® versus UDT plus placebo) of 1.5. The
hazard ratio and one-sided 96% confidence interval will
be obtained from the Cox regression model with treat-
ment and center effects. The non-inferiority will be sup-
ported by the result that the upper bound of the
confidence interval is below 1.5. The proportional haz-
ards assumption underlying the Cox model will be exam-
ined with appropriate alternative statistical models
applied. Results based on the ITT analysis set will be con-
sidered primary and those based on EPP analysis support-
ive. The secondary safety endpoint is the time to the
occurrence of first cardiovascular SAEs (myocardial infarc-
tion, stroke, in-patient hospitalization for heart failure,
angina or revascularization surgery). These endpoints will
be analyzed in the same manner as described above for
the primary endpoint
Other clinical measures
Clinical efficacy analyses will also be conducted for sub-
jects taking any oral hypoglycemic agent (OHA) or inject-BMC Endocrine Disorders 2007, 7:3 http://www.biomedcentral.com/1472-6823/7/3
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able insulin secretagogue with a baseline HbA1c of ≥
7.5%. Additional subsets of this population include those
receiving a) metformin with or without any OHA or
injectable insulin secretagogue and b) sulphonylurea with
or without any OHA or injectable insulin secretagogue.
The difference in the change in the HbA1c from baseline
to 24 weeks between Cycloset™ and placebo will be the
primary efficacy measure. The analyses will be based on
both a) ITT – last observation carry forward method and
b) subjects with an HbA1c measurement at week 24 (com-
pleters). An analysis of covariance (ANCOVA) model will
be used to test for a treatment difference while adjusting
for the baseline hemoglobin A1c value and center effect.
Additional analyses will be used to assess the impacts
from additional risk factors by including additional terms
such as age, gender, body mass index at baseline, duration
of disease history, and concomitant medications. Any sig-
nificant effects from these potential risk factors will be fur-
ther investigated. Analyses of treatment group differences
in change from baseline in fasting plasma glucose, weight,
waist circumference, triglycerides, lipid profile, and blood
pressure will be explored within these defined groups.
We will also provide descriptive statistics on the changes
in concomitant diabetes medications during the observa-
tional period (proportion of subjects adding therapy or
increasing dose of preexisting therapy; proportion stop-
ping therapy or decreasing dose; proportion not changing
therapy). If warranted, additional analyses will assess the
impact of such changes in concomitant diabetes medica-
tions during the observation period on difference between
Cycloset™ and placebo in change from baseline in HbA1c.
Sub-study efficacy analyses
Metformin/sulfonylurea efficacy analysis
The Intention-To-Treat efficacy analysis set (ITTe) will
include all subjects who were randomized to the study
and at the time of screening were treated with metformin
plus a sulfonylurea and had a screening HbA1c of ≥ 7.5%,
and received at least one dose of study treatment (either
Cycloset™ or placebo). The change in the HbA1c from
baseline (screening visit week-2) to 24 weeks will be the
primary efficacy measure. An analysis of covariance
(ANCOVA) model will be used to test for a treatment dif-
ference while adjusting for the baseline hemoglobin A1c
value and center effect. For those patients who discontin-
ued prior to 24 weeks, the last post-randomization obser-
vation will be carried forward. The Evaluable Per-Protocol
efficacy analysis (EPPe) set will consist of those ITT sub-
jects with no major protocol violations and with an
Hba1c measurement at 24 weeks. Analyses of treatment
group differences in change from baseline in fasting
plasma glucose, weight, waist circumference, triglycerides,
lipid profile, and blood pressure will be explored.
Prior to un-blinding the study data it is not possible to
consider all possible adjustments needed to fully develop
the appropriate model for determining changes in various
efficacy parameters. We will further explore and deploy
the appropriate methods of statistical analysis to fully dis-
cern the differences between Cycloset™ and placebo in
this large study.
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